1. Jazz Pharmaceuticals authorized for Ziihera in EU, targeting HER2-positive cancer. 2. Revised 2025 earnings forecast drastically reduced from $22.50-$24 to $4-$5.60. 3. The stock is undervalued at $110 with strong revenue growth prospects. 4. High debt and historical downturn sensitivity pose risks for investors. 5. Analyst estimates suggest a potential price increase to $188.
The stock is undervalued given its strong pipeline and future earnings potential. Historical examples, like stocks bouncing back after approvals, indicate recovery opportunities.
The article discusses significant corporate developments and future potential, highly relevant for stakeholders in JAZZ.
Future sales from Ziihera and dordaviprone will manifest in coming years, and may stabilize earnings. Historical rebounds in stock prices post-approval support this view.